Cautious Hold Rating on Intellia Therapeutics Amid Safety Concerns and Regulatory Uncertainty

William Blair analyst Myles Minter has reiterated their neutral stance on NTLA stock, giving a Hold rating on October 31.

Myles Minter has given his Hold rating due to a combination of factors surrounding Intellia Therapeutics. A significant concern is the recent unfortunate death of a patient in the ATTR-CM trial, which has led to a substantial drop in the company’s stock price. The patient, who was treated with the drug nex-z, experienced severe adverse effects, raising questions about the drug’s safety profile.
While the management remains optimistic about other projects like lonvo-z and the potential success of ongoing studies, the immediate focus is on understanding the safety issues with nex-z. The company is awaiting further clarification from the FDA, and the outcome of the ongoing investigation will be crucial. Until there is a clear regulatory path and a mechanistic explanation for the adverse event, Minter maintains a cautious stance, reflected in the Hold rating.

According to TipRanks, Minter is a 5-star analyst with an average return of 29.1% and a 59.85% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Biogen, and Argenx Se.

In another report released on October 31, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $12.50 price target.